drugset / Trial / NCT01303445

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445

Phase 1 Completed 60 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-label

Summary

The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics of dipyridamole and the pharmacodynamics of ASA-induced platelet aggregation inhibition (components of Aggrenox®) when administered every 12 hours at steady state.

Timeline

Start
2011-03
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator ASA Unknown
Comparator Dipyridamole Other / unclassified
Subject Omeprazole Other / unclassified 80 mg

Indications

No indication recorded.